Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 5 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Emricasan ineffective in NASH patients

01 May 2020

Emricasan appears to be ineffective in improving liver histology in patients with nonalcoholic steatohepatitis (NASH) and may even worsen fibrosis and ballooning, a new trial has shown.

Researchers randomly assigned 318 NASH patients 1:1:1 to receive twice-daily emricasan, at 5 or 50 mg, or matching placebo. The trial lasted for 72 weeks, over which time efficacy was measured as the improvement of at least one NASH Clinical Research Network (CRN) fibrosis stage without further worsening.

NASH resolution was infrequent on both the 5-mg and 50-mg emricasan doses than on placebo (3.7 percent vs 6.6 percent vs 10.5 percent). The same was true for the resolution of fibrosis (3.7 percent vs 0.9 percent vs 4.9 percent, respectively) and disease activity score response (10.3 percent vs 9.4 percent vs 18.1 percent, respectively).

Moreover, more placebo patients saw improvements in fibrosis relative to the 5-mg and 50-mg emricasan dose groups (21.5 percent vs 13.7 percent and 13.4 percent).

On the other hand, emricasan patients showed a significant increase in fibrosis stage from baseline (5-mg: least squares mean [LSM] change, 0.405, 95 percent confidence interval [CI], 0.237–0.572; p=0.004; 50-mg: LSM change, 0.357, 95 percent CI, 0.191–0.523; p=0.013).

The corresponding change in the placebo group was nonsignificant (LSM change, 0.061, 95 percent CI, –0.108 to 0.230). There were also fewer patients in the placebo group who experienced worsening fibrosis than in the 5-mg and 50-mg emricasan groups (20.4 percent vs 41.1 percent and 38.1 percent).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 5 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.